Research programme: antisense oligonucleotides - Capricor Therapeutics
Latest Information Update: 24 Oct 2023
At a glance
- Originator Capricor Therapeutics
- Class Antisense oligonucleotides; Exosome therapies
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 10 Oct 2023 Research programme: antisense oligonucleotides - Capricor Therapeutics is available for licensing as of 10 Oct 2023 (https://www.capricor.com/)
- 10 Oct 2023 Preclinical trials in Duchenne muscular dystrophy in USA (Parenteral) before October 2023
- 10 Oct 2023 Pharmacodynamics data from a preclinical trial in Duchenne muscular dystrophy released by Capricor Therapeutics